A century of medical progress—and concussion patients are still largely told to rest and wait. Could OXE103 help change that?
Former NFL quarterback Alex Smith and Oxeia Biopharmaceuticals CEO Dr. Michael Wyand join Paul Frase to examine one of the largest gaps in brain-injury care: the lack of an FDA-approved medication for concussion.
Alex shares what concussions looked and felt like during his 16-year NFL career—and why his experiences led him to join Oxeia’s Board of Directors. Dr. Wyand explains what happens inside the brain following a concussion, the science behind OXE103, and why its early Phase 2a results justified taking the research into a larger, controlled Phase 2b trial.
The conversation explores why “rest and wait” is not enough, what scientists still need to prove, and what an effective treatment could mean for athletes, veterans, accident survivors, children and families living with persistent concussion symptoms.
OXE103 is investigational and has not been approved by the FDA. This episode is for educational purposes and should not be considered medical or investment advice.
Sponsors
This episode is presented in partnership with
Oxeia Biopharmaceuticals:
oxeiabiopharma.comThe HeadRush Podcast proudly recognizes the support of:
Please support the HeadRush Foundation as it expands brain-health education, resources, treatment access and hope for individuals and families affected by brain injury.